- Brand names:
- Pharmaceutical Company:
- Condition/Indication:
- Meeting Date: July 2017
- Public Summary Document (PSD) July 2017 PBAC Meeting - PDF
- Public Summary Document (PSD) July 2017 PBAC Meeting - Word
Adalimumab – July 2017
Adalimumab: Injection 40 mg in 0.8 mL vial; Humira®
Last updated
26 October 2018